DarioHealth Amends Preferred Stock Designations

DarioHealth ( (DRIO) ) has provided an announcement.

On May 20, 2025, DarioHealth filed amended and restated certificates of designation for its Series A-1 and Series B-1 preferred stocks with the Secretary of State of Delaware. This amendment allows holders of these preferred stocks to request dividends and distributions in the form of pre-funded common stock purchase warrants instead of common stock, without issuing or selling additional securities.

The most recent analyst rating on (DRIO) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on DarioHealth stock, see the DRIO Stock Forecast page.

Spark’s Take on DRIO Stock

According to Spark, TipRanks’ AI Analyst, DRIO is a Neutral.

DarioHealth’s overall performance is hindered by financial challenges, despite some positive operational and strategic developments. The company’s ability to improve profitability and manage debt will be crucial for future prospects. Technical and valuation metrics are mediocre, reflecting market skepticism.

To see Spark’s full report on DRIO stock, click here.

More about DarioHealth

Average Trading Volume: 240,217

Technical Sentiment Signal: Sell

Current Market Cap: $31.91M

For an in-depth examination of DRIO stock, go to TipRanks’ Stock Analysis page.